Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients
1998

Study of Paclitaxel for Liver Cancer

Sample size: 20 publication Evidence: low

Author Information

Author(s): Y Chao, W-K Chan, MJ Birkhofer, OY-P Hu, S-S Wang, Y-S Huang, M Liu, J Whang-Peng, K-H Chi, W-Y Lui, S-D Lee

Primary Institution: Veterans General Hospital-Taipei and National Yang-Ming University

Hypothesis

Does paclitaxel have any significant anti-cancer effect in patients with unresectable hepatocellular carcinoma?

Conclusion

Paclitaxel has no significant anti-cancer effect in patients with unresectable hepatocellular carcinoma.

Supporting Evidence

  • No complete or partial responses were observed in the study.
  • The median survival of patients was 12 weeks.
  • Treatment-related deaths occurred in two patients.

Takeaway

This study tested a cancer drug called paclitaxel on patients with a serious liver cancer, but it didn't help them get better.

Methodology

Patients received paclitaxel intravenously every 3 weeks, and their responses and side effects were monitored.

Limitations

The study had a small sample size and no complete or partial responses were observed.

Participant Demographics

Median age was 64 years, all patients had cirrhosis, and most had chronic hepatitis B or C.

Statistical Information

P-Value

p=0.03

Statistical Significance

p<0.02

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication